Carnevale Maria Grazia, Colciago Riccardo Ray, De Santis Maria Carmen, Cortesi Laura, De Marco Cinzia, Marra Antonio, Vingiani Andrea, Nolè Franco, Curigliano Giuseppe, Pruneri Giancarlo, Llombart-Cussac Antonio, Di Cosimo Serena, Cortes Javier
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy.
Bicocca University, Milano, Italy.
Breast. 2025 May 8;82:104488. doi: 10.1016/j.breast.2025.104488.
Advances in cancer biology and drug development now enable treatments tailored to individual tumor profile. Targeting specific molecular alterations marked a significant step forward in cancer care, including breast cancer. Access to these therapies is improving thanks to the implementation of molecular tumor boards and efforts to provide molecular diagnostics at sustainable costs for all. In this context, we highlight recent progress in breast cancer therapy, focusing on biomarker-driven approaches, immunotherapy, and precision medicine paving the way for increasingly personalized and effective options.
癌症生物学和药物开发的进展如今使得能够根据个体肿瘤特征定制治疗方案。针对特定分子改变是癌症治疗（包括乳腺癌治疗）向前迈出的重要一步。由于分子肿瘤学委员会的设立以及为所有人提供可持续成本的分子诊断所做的努力，这些疗法的可及性正在改善。在此背景下，我们重点介绍乳腺癌治疗的最新进展，着重于生物标志物驱动的方法、免疫疗法以及为越来越个性化和有效的治疗选择铺平道路的精准医学。
